Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B

Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B

Source: 
Endpoints
snippet: 

Having already found a painless cure for hepatitis C, Gilead has now set its sights on another cure for hepatitis B. And they’ve steered around the most prominent gene-editing players in the field to partner up Durham, NC-based Precision BioSciences just a couple of months after the biotech raised an impressive $110 million mega-crossover round.